Common Contracts
8 similar Underwriting Agreement contracts by BioPharmX Corp, Celcuity Inc., Celcuity LLC, others
EDAP TMS S.A. 2,666,667 American Depositary Shares Representing 2,666,667 Ordinary Shares (Nominal Value €0.13 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 26th, 2022 • Edap TMS Sa • Electromedical & electrotherapeutic apparatus • New York
The ADSs delivered to the Underwriters hereunder shall be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to the Deposit Agreement (the “Deposit Agreement”) dated as of July 31, 1997 and amended and restated as of April 7, 2008, by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”) and all owners and beneficial owners from time to time of the ADRs.
●] Shares1 HyreCar Inc. Common Stock, par value $0.00001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2019 • HyreCar Inc. • Services-auto rental & leasing (no drivers) • New York
HyreCar Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.00001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
1,636,364 Shares1 iCAD, Inc. Common Stock, par value $0.01 per share UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2019 • Icad Inc • Surgical & medical instruments & apparatus • New York
iCAD, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,636,364 shares (the “Firm Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to 245,454 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (the “Agreement”) are herein collectively called the “Securities.”
2,400,000 Shares1 celcuity Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • September 25th, 2017 • Celcuity Inc. • Services-medical laboratories • New York
Celcuity Inc., a Delaware corporation (together with its predecessor entity, Celcuity LLC, a Minnesota limited liability company, in existence prior to conversion to a Delaware corporation, the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,400,000 authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company also has granted to the several Underwriters an option to purchase up to 360,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
l] Shares1 celcuity Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • September 12th, 2017 • Celcuity LLC • Services-medical laboratories • New York
4,500,000 Shares Merit Medical Systems, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2017 • Merit Medical Systems Inc • Surgical & medical instruments & apparatus • New York
Merit Medical Systems, Inc., a Utah corporation (the “Company”), proposes to sell to Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Piper Jaffray & Co. (“Piper Jaffray”, and together with Merrill Lynch, the “Representatives”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof) an aggregate of 4,500,000 shares (the “Firm Shares”) of Common Stock, no par value per share (the “Common Stock”), of the Company. The Company has also granted to the Underwriters an option to purchase up to 675,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
● ] Shares Spring Bank Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 9th, 2016 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair and Company, L.L.C. and Wedbush Securities Inc. are acting as representatives (the “Representatives” or “you”) an aggregate of [ ● ] shares (the “Firm Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and, at the election of the Underwriters, subject to the terms and conditions stated herein, the Company shall issue and sell up to [ ● ] additional shares (the “Option Shares”) of Common Stock. The Firm Shares and any Option Shares purchased pursuant Section 3 hereof are herein collectively called the “Securities.”
3,636,364 Shares of Common Stock BioPharmX Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • June 26th, 2015 • BioPharmX Corp • Construction - special trade contractors • New York
BioPharmX Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,636,364 shares (the “Firm Shares”) of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”). The Company has also granted to the Underwriters an option to purchase up to 545,454 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (the “Agreement”) are herein collectively referred to as the “Shares.”
